Cancer chemopreventative composition and method

• US 6,008,260 A
• Filed: 01/09/1998
• Issued: 12/28/1999
• Est. Priority Date: 01/09/1998
• Status: Expired due to Term

• Current Assignee: Pharmascience Incorporated (Joddes Limitã©E)
• Original Assignee: Pharmascience Incorporated (Joddes Limitã©E)
• Inventors: Moon, Richard C., Pezzuto, John M., Jang, Mei-Shiang
• Primary Examiner(s): Goldberg, Jerome D.
• Application Number:
  US09/005,114
• Time in Patent Office: 718 Days
• Field of Search: 514/733, 514/736
• US Class Current: 514/733
• CPC Class Codes: A23L 33/105 Plant extracts, their artificial duplicates or their derivatives
• CPC Class Codes: A61K 31/05 Phenols cannabinoids A61K31/658
• CPC Class Codes: A61K 47/549 Sugars, nucleosides, nucleotides or nucleic acids
• CPC Class Codes: A61K 8/347 Phenols
• CPC Class Codes: A61K 8/60 Sugars; Derivatives thereof
• CPC Class Codes: A61Q 19/08 Anti-ageing preparations
• CPC Class Codes: B82Y 5/00 Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Abstract

A composition and method of cancer chemoprevention is disclosed. The composition and method utilize resveratrol as a cancer chemopreventative agent in mammals, including humans.

Claims

1. A method of chemopreventing cancer comprising administering a cancer chemopreventative composition to a mammal in need thereof in a sufficient amount to suppress the initiation, promotion, or progression of a cancer, said composition comprising resveratrol and said cancer selected from the group consisting of a mammary cancer, a skin cancer, human leukemia, a heptoma, a colon cancer, a chemically induced neoplastic transformation, and a neoplastic transformation due to oxidative damage.

2. The method of claim 1 wherein the composition is a solid.

3. The method of claim 1 wherein the composition is a liquid.

4. The method of claim 1 wherein the composition is administered topically.

5. The method of claim 1 wherein the composition is administered orally.

6. The method of claim 1 wherein the composition is administered parenterally.

7. The method of claim 1 wherein the composition is a food additive.

8. The method of claim 1 wherein the composition is a pharmaceutical.

9. The method of claim 1 wherein the composition is administered in a sufficient amount to provide a measurable increase in phase II enzymes.

10. The method of claim 1 wherein the composition is administered in an amount of about 0.005 to about 1 micromoles per kg per day.

11. The method of claim 1 wherein the composition is administered in an amount of about 0.05 to about 0.75 micromoles per kg per day.

12. The method of claim 1 wherein the composition is administered in an amount of about 0.075 to about 0.5 micromoles per kg per day.

13. The method of claim 1 wherein the composition is administered prior to exposure of the mammal to a carcinogen or a procarcinogen.

14. The method of claim 1 wherein the composition is administered during or after exposure of the mammal to a carcinogen or a procarcinogen.

15. The method of claim 1 wherein the mammal is a human.

16. The method of claim 15 wherein the composition is administered in a sufficient amount to produce a suppressing effect on a tumor associated with the cancer.